Therapy Detail

Therapy Name Tivozanib
Therapy Description

Tivozanib (AV-951) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tivozanib AV-951 VEGFR Inhibitor (Pan) 29 Tivozanib (AV-951) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown renal cell carcinoma not applicable Tivozanib Phase III Actionable In a Phase III trial, Tivozanib (AV-951) demonstrated improved progression free survival compared with Nexavar (sorafenib) as initial targeted therapy in patients with metastatic renal cell carcinoma (PMID: 24019545). 24019545
Unknown unknown Advanced Solid Tumor not applicable Tivozanib Phase I Actionable In a Phase I clinical study, Tivozanib (AV-951) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Clin Cancer Res, November 15, 2011 17; 7156). detail...
Unknown unknown fibrosarcoma not applicable Tivozanib Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with Tivozanib (AV-951) resulted in partial inhibition of tumor growth and decreased tumor vasulature in a fibrosarcoma cell line xenograft model (PMID: 25995436). 25995436
Clinical Trial Phase Therapies Title Recruitment Status
NCT01972516 Phase II Tivozanib Tivozanib As Maintenance Therapy In GYN Terminated
NCT02627963 Phase III Sorafenib Tivozanib A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC Active, not recruiting
NCT01853644 Phase II Tivozanib Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting
NCT01835223 Phase Ib/II Tivozanib Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery Active, not recruiting